Conference abstractPublished 26 Oct 2015
CHALLENGES IN PROCESS DEVELOPMENT, SCALE UP, BULK MANUFACTURING OF LOW VOLUME HIGH VALUE BILOGICS & BIOSIMILARS: GLOBAL AND INDIAN PROSPECT
Bills Biotech, India
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The biologics market consists primarily of vaccines, monoclonal antibodies, recombinant proteins and diagnostics. Global pharmaceutical market projected of the growth rate 12%, Growth in biopharmaceutical market,to reach US$138 bn by 2014,dominated by products from mammalian cell cultures (>75%). Global biosimilars market ≈ $19.4 billion by 2014, growing at an expected CAGR of 89.1% from 2009 to 2014.By 2015, sales of biosimilars in US are expected US$1.9-2.6 billion, up from US$378 million in 2011.There is great opportunities in biopharmaceuticals, novel biologics & biosimilar r-proteins, Vaccines development and process parameter set up.Different scale-up criteria have been used depending on the type of fermentation and bioreactors. Growing mammalian cells in fermenters/bioreactors and to produce the protein of interest is a very cautious process and process parameters like pH or dissolved oxygen concentration need to be controlled very strictly to corroborate the consistency of a product. Minor deviations of the predefined process parameters can easily result in changes of product quality attributes like glycosylation, aggregation, c-terminal clipping or acidic variation, which can affect the pharmacokinetics of the protein e.g. case study for eryhtropoetin,Darbepoetin,Mabs etc..In reality scale-up of laboratory and pilot-plant data to commercial size industrial bioreactors is complicated.No actual data or correlation or exisiting formula is fixed for scale-up. Different people use different scale-up criteria to design commercial size bioreactor systems.In fermentation industry there are a lot of trade secrets on scale-up of bioreactors and fermentors , and very few published results.
Subjects
EngineeringAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectEngineering
- BylineArticles whose byline prints “Sumant Chaubey”